Search

Displaying results 1471 - 1480 of 1723 in total
  1. Drug

    Chlorhexidine

    go.drugbank.com/drugs/DB00878
    ApprovedInvestigationalVet approvedWithdrawn

    [L11572] The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use

  2. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    It is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [

  3. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    [A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]

  4. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).

  5. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  6. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    The FDA considers carbamide peroxide to be safe in oral mucosal injury drug products as an oral wound healing agent, although there is insufficient data to establish general recognition of the effectiveness

  7. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

  8. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for

  9. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.

  10. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]